Leaflet:information for the user
EplerenonAristo 25 mgfilm-coated tablets
Eplerenona Aristo 50 mg film-coated tablets
Read this leaflet carefully before you start taking this medicine because it contains important information for you.
1.What isEplerenonAristoand what it is used for
2.What you need to know before starting to takeEplerenonAristo
3.How to takeEplerenonAristo
4.Possible side effects
5.Storage ofEplerenonAristo
6.Contents of the pack and additional information
EplerenoneAAristo belongs to a group of medicines known as selective aldosterone blockers. These blockers inhibit the action of aldosterone, a substance produced by the body that controls blood pressure and cardiac function. Elevated levels of aldosterone can produce changes in the body that lead to heart failure.
EplerenoneAAristo is used to treat heart failure to prevent worsening and reduce hospitalization if you have:
Do not take Eplerenonto Aristo
Warnings and precautions
Consult your doctor or pharmacist before starting to take Eplerenon to Aristo:
Pediatric population
The safety and efficacy of eplerenone in children and adolescents have not been established.
Use of Eplerenon to Aristo with other medicines
Inform your doctor or pharmacist that you are using, have used recently or may need to use any other medicine.
You should not take Eplerenon to Aristo with the following medicines (see section "Do not use Eplerenon to Aristo"):
Inform your doctor if you are taking any of the following medicines:
Taking Eplerenon to Aristo with food and drinks
Eplerenon to Aristo can be taken with or without food.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medicine.Eplerenon to Aristo has not been evaluated in humans during pregnancy.
The safety of eplerenone during breastfeeding is unknown. Your doctor will decide with you whether to stop treatment or breastfeeding.
Driving and operating machinery
After taking Eplerenon to Aristo, you may feel dizzy. If this happens, do not drive or operate machinery.
Eplerenon to Aristo contains lactose monohydrate
Eplerenon to Aristo contains lactose monohydrate (a type of sugar). If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medicine.
Eplerenona Aristo contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist.In case of doubt, consult your doctor or pharmacist again.
Eplerenon Aristo tablets can be taken with or without food. Swallow the tablets whole with plenty of water.
Eplerenon Aristo is usually administered together with other medications for heart failure, for example, beta-blockers. The usual initial dose is one 25 mg tablet once a day, increasing after 4 weeks to 50 mg daily (one 50 mg tablet or two 25 mg tablets). The maximum dosage regimen is 50 mg per day.
Blood potassium determinations should be performed before starting treatment with Eplerenon Aristo, during the first week, and one month after starting treatment or after a change in dose. Your doctor may adjust the dose based on your blood potassium levels.
Patients with liver or kidney problems
If you have mild renal insufficiency, you should start treatment with one 25 mg tablet per day, and if you have moderate renal insufficiency, you should start treatment with one 25 mg tablet every other day. These doses may be adjusted, if your doctor indicates, and in accordance with your blood potassium levels.
Eplerenon Aristo is not recommended for patients with severe renal disease.
No initial dose adjustment is necessary for patients with mild to moderate liver insufficiency. If you have any liver or kidney disease, you may need to have your blood potassium levels checked more frequently (see also “Do not take Eplerenon Aristo”).
Patients of advanced age
In patients of advanced age: no initial dose adjustment is required.
Use in children and adolescents
In children and adolescents: Eplerenon Aristo is not recommended.
If you take more Eplerenon Aristo than you should
If you take more Eplerenon Aristo than you should, inform your doctor or pharmacist immediately. If you have taken too much medication, the most likely symptoms will be low blood pressure (manifested as dizziness, blurred vision, weakness, acute loss of consciousness) or hyperkalemia, high levels of potassium in the blood (manifested by muscle cramps, diarrhea, nausea, dizziness, or headache).
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Eplerenon Aristo
If it is almost time to take the next tablet, skip the dose you forgot and take the next tablet at the usual time.
Otherwise, take the tablet as soon as you remember, provided it has been more than 12 hours since the time you usually take the next tablet. Resume your medication as usual.
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Eplerenon Aristo
It is essential to continue taking Eplerenon Aristo as instructed, unless your doctor tells you to stop treatment.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can produce adverse effects, although not all people will experience them.
If any of the following occur:
Seek immediate medical attention
These are symptoms of angioneurotic edema, a rare adverse effect (affecting up to 1 in 100 people).
Other reported adverse effects include:
Frequent adverse effects(may affect up to 1 in 10 people):
Rare adverse effects(may affect up to 1 in 100 people):
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through theSpanish System for Pharmacovigilance of Medicinal Products for Human Use, webpage:www.notificaRAM.es
By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keepthis medicationout of the sight and reach of children.
This medication does not require special storage conditions.
Do not usethis medicationafter the expiration date that appears onthe packaging and outer carton after CAD.The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or trash. Dispose of the containers and medicationsthat you no longer need at the SIGREpoint at the pharmacy. Ask your pharmacisthow to dispose ofthecontainers and medications that you no longerneed.By doing so, you will help protect the environment.
Eplerenone CompositionaAristo
The active ingredient of the film-coated tablets of Eplerenona Aristo is eplerenone. Each tablet contains 25 mg or 50 mg of eplerenone.
Eplerenona Aristo 25 mg and 50 mg film-coated tablets EFG also contain the following components: Lactose monohydrate, microcrystalline cellulose (E460), sodium croscarmellose (Typo A), hypromellose (Benecel E3), talc, and magnesium stearate.
The opadry yellow coating of Eplerenona Aristo 25 mg and 50 mg film-coated tablets contains macrogol/PEG 6000, HPMC 2910/hypromellose 5cP, talc (E553b), titanium dioxide (E171), yellow iron oxide (E172), and red iron oxide (E172).
Appearance of the product and contents of the package
The EplerenonaAristo 25 mg tablet is a film-coated, biconvex, round, yellow tablet, with “E25” engraved on one side
The EplerenonaAristo 50 mg tablet is a film-coated, biconvex, round, yellow tablet, with “E50” engraved on one side
EplerenonaAristo 25 mg and 50 mg film-coated tablets are presented in blisters of PVC opaque-Aluminium containing 10, 20, 28, 30, 50, 90, 100, or 200 film-coated tablets.
Only some package sizes may be marketed.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Aristo Pharma Iberia, S.L.
C/Solana, 26
28850 Torrejón de Ardoz, Madrid
Spain
Responsible manufacturer
Pharmathen S.A.
6, Dervenakion str.
15351 Pallini, Attiki
Greece
Pharmathen International SA
Sapes Industrial Park Block 5
69300 Rodopi
Greece
G.L. Pharma GmbH
Schlossplatz 1, 8502 Lannach
Austria
This medicinal product is authorized in the member states of the European Economic Area with the following names:
Denmark25mg: Eplerenon Pharmathen
50mg: Eplerenon Pharmathen
Iceland25mg: Eplerenone Algoven
50mg: Eplerenone Algoven
Austria25mg: Eplezot 25mg Filmtabletten
50mg: Eplezot 50mg Filmtabletten
Poland25mg: Eplenocard
50mg: Eplenocard
Greece25mg: Vaner
50mg: Vaner
Spain25mg: EplerenonaAristofilm-coated tablets EFG
50mg: EplerenonaAristofilm-coated tablets EFG
Last date of revision of this leaflet:July2022
The detailed and updated information of this medicinal product is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.